Literature DB >> 18936910

Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.

José A Martínez1, Esther Delgado, Sara Martí, Francesc Marco, Jordi Vila, Josep Mensa, Antoni Torres, Carles Codina, Antoni Trilla, Alex Soriano, Aitor Alquezar, Pedro Castro, José M Nicolás.   

Abstract

OBJECTIVE: To assess the role of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance.
DESIGN: Prospective cohort study.
SETTING: Two medical intensive care units. PATIENTS AND PARTICIPANTS: 346 patients admitted for >or= 48 h. INTERVENTION: Analysis of data from an 8-month study comparing a mixing versus a cycling strategy of antibiotic use. MEASUREMENTS AND
RESULTS: Surveillance cultures from nares, pharynx, rectum, and respiratory secretions were obtained thrice weekly. Acquisition of resistance was defined as the isolation, after 48 h of ICU stay, of an isolate resistant to a given antibiotic if culture of admission samples were either negative or positive for a susceptible isolate. Emergence of resistance refers to the conversion of a defined pulsotype from susceptible to non-susceptible. Forty-four (13%) patients acquired 52 strains of P. aeruginosa. Administration of piperacillin-tazobactam for >or= 3 days (OR 2.6, 95% CI 1.09-6.27) and use of amikacin for >or= 3 days (OR 2.6, 95% CI 1.04-6.7) were positively associated with acquisition of P. aeruginosa, whereas use of quinolones (OR 0.27, 95% CI 0.1-0.7) and antipseudomonal cephalosporins (OR 0.27, 95% CI 0.08-0.9) was protective. Exposure to quinolones and cephalosporins was not associated with the acquisition of resistance, whereas it was linked with usage of all other agents. Neither quinolones nor cephalosporins were a major determinant on the emergence of resistance to themselves, as resistance to these antibiotics developed at a similar frequency in non-exposed patients.
CONCLUSIONS: In critically ill patients, quinolones and antipseudomonal cephalosporins may prevent the acquisition of P. aeruginosa and may have a negligible influence on the acquisition and emergence of resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936910     DOI: 10.1007/s00134-008-1326-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  39 in total

1.  Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients.

Authors:  D Lepelletier; N Caroff; D Riochet; P Bizouarn; A Bourdeau; F Le Gallou; E Espaze; A Reynaud; H Richet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

2.  Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control.

Authors:  M J Bonten; D C Bergmans; H Speijer; E E Stobberingh
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

3.  Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer.

Authors:  Norio Ohmagari; Hend Hanna; Linda Graviss; Brenda Hackett; Cheryl Perego; Virginia Gonzalez; Tanya Dvorak; Holly Hogan; Ray Hachem; Kenneth Rolston; Issam Raad
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

4.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

6.  Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients.

Authors:  Bryan Ortega; A B Johan Groeneveld; Constance Schultsz
Journal:  Infect Control Hosp Epidemiol       Date:  2004-10       Impact factor: 3.254

7.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Nosocomial infections in adult intensive-care units.

Authors:  Jean-Louis Vincent
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.

Authors:  C Peña; A Guzmán; C Suarez; M A Dominguez; F Tubau; M Pujol; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

View more
  14 in total

1.  Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study.

Authors:  M Montero; M Sala; M Riu; F Belvis; M Salvado; S Grau; J P Horcajada; F Alvarez-Lerma; R Terradas; M Orozco-Levi; X Castells; H Knobel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-24       Impact factor: 3.267

2.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

3.  Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients.

Authors:  Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Elisabet Periche; Rosario Cañizares; M Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

4.  Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICU.

Authors:  N Cobos-Trigueros; M Rinaudo; M Solé; P Castro; J Pumarol; C Hernández; S Fernández; J M Nicolás; J Mallolas; J Vila; L Morata; J M Gatell; A Soriano; J Mensa; J A Martínez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-23       Impact factor: 3.267

Review 5.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009-2013).

Authors:  Y M Zou; Y Ma; J H Liu; J Shi; T Fan; Y Y Shan; H P Yao; Y L Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-10       Impact factor: 3.267

Review 7.  Year in review in Intensive Care Medicine 2009: I. Pneumonia and infections, sepsis, outcome, acute renal failure and acid base, nutrition and glycaemic control.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2010-01-08       Impact factor: 17.440

8.  Pseudomonas aeruginosa blood stream infection isolates from patients with recurrent blood stream infection: Is it the same genotype?

Authors:  K L McCARTHY; T J Kidd; D L Paterson
Journal:  Epidemiol Infect       Date:  2017-08-22       Impact factor: 4.434

9.  Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure.

Authors:  Nazaret Cobos-Trigueros; Mar Solé; Pedro Castro; Jorge Luis Torres; Cristina Hernández; Mariano Rinaudo; Sara Fernández; Álex Soriano; José María Nicolás; Josep Mensa; Jordi Vila; José Antonio Martínez
Journal:  Crit Care       Date:  2015-05-04       Impact factor: 9.097

10.  Surveillance and correlation of antimicrobial usage and resistance of Pseudomonas aeruginosa: a hospital population-based study.

Authors:  Jiancheng Xu; Xiumei Duan; Hui Wu; Qi Zhou
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.